644 related articles for article (PubMed ID: 37057121)
21. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Rolfo C; Mack P; Scagliotti GV; Aggarwal C; Arcila ME; Barlesi F; Bivona T; Diehn M; Dive C; Dziadziuszko R; Leighl N; Malapelle U; Mok T; Peled N; Raez LE; Sequist L; Sholl L; Swanton C; Abbosh C; Tan D; Wakelee H; Wistuba I; Bunn R; Freeman-Daily J; Wynes M; Belani C; Mitsudomi T; Gandara D
J Thorac Oncol; 2021 Oct; 16(10):1647-1662. PubMed ID: 34246791
[TBL] [Abstract][Full Text] [Related]
22. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
23. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
[TBL] [Abstract][Full Text] [Related]
24. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
25. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
26. Update on liquid biopsy in clinical management of non-small cell lung cancer.
Wu Z; Yang Z; Dai Y; Zhu Q; Chen LA
Onco Targets Ther; 2019; 12():5097-5109. PubMed ID: 31303765
[TBL] [Abstract][Full Text] [Related]
27. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
Heitzer E; van den Broek D; Denis MG; Hofman P; Hubank M; Mouliere F; Paz-Ares L; Schuuring E; Sültmann H; Vainer G; Verstraaten E; de Visser L; Cortinovis D
ESMO Open; 2022 Apr; 7(2):100399. PubMed ID: 35202954
[TBL] [Abstract][Full Text] [Related]
28. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
29. Overview of the role of liquid biopsy in cancer management.
Assi T; Khoury R; Ibrahim R; Baz M; Ibrahim T; LE Cesne A
Transl Oncol; 2023 Aug; 34():101702. PubMed ID: 37267803
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA - Current state of play and future perspectives.
De Rubis G; Krishnan SR; Bebawy M
Pharmacol Res; 2018 Oct; 136():35-44. PubMed ID: 30142423
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.
Caputo V; Ciardiello F; Corte CMD; Martini G; Troiani T; Napolitano S
Explor Target Antitumor Ther; 2023; 4(1):102-138. PubMed ID: 36937316
[TBL] [Abstract][Full Text] [Related]
32. Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
Chang S; Hur JY; Choi YL; Lee CH; Kim WS
J Pathol Transl Med; 2020 May; 54(3):204-212. PubMed ID: 32460474
[TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy for lung cancer early detection.
Santarpia M; Liguori A; D'Aveni A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; Lazzari C; Altavilla G; Rosell R
J Thorac Dis; 2018 Apr; 10(Suppl 7):S882-S897. PubMed ID: 29780635
[TBL] [Abstract][Full Text] [Related]
34. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors.
Pinzani P; D'Argenio V; Del Re M; Pellegrini C; Cucchiara F; Salvianti F; Galbiati S
Clin Chem Lab Med; 2021 Jun; 59(7):1181-1200. PubMed ID: 33544478
[TBL] [Abstract][Full Text] [Related]
35. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy and NSCLC.
Trombetta D; Sparaneo A; Fabrizio FP; Muscarella LA
Lung Cancer Manag; 2016 Jun; 5(2):91-104. PubMed ID: 30643553
[TBL] [Abstract][Full Text] [Related]
37. Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.
Kapeleris J; Ebrahimi Warkiani M; Kulasinghe A; Vela I; Kenny L; Ladwa R; O'Byrne K; Punyadeera C
Front Oncol; 2022; 12():859152. PubMed ID: 35372000
[TBL] [Abstract][Full Text] [Related]
38. Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer.
Hirahata T; Ul Quraish R; Quraish AU; Ul Quraish S; Naz M; Razzaq MA
Cancer Inform; 2022; 21():11769351221076062. PubMed ID: 35153470
[TBL] [Abstract][Full Text] [Related]
39. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
40. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer.
Saarenheimo J; Eigeliene N; Andersen H; Tiirola M; Jekunen A
Front Oncol; 2019; 9():129. PubMed ID: 30891428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
